Momelotinib is a potent, selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis (MF).

Data from more than 820 patients with MF suggest that momelotinib can markedly improve constitutional symptoms and splenomegaly while also substantially addressing the chronic anemia and transfusion dependency associated with the disease.

Sierra has launched MOMENTUM, a randomized double-blind Phase 3 clinical trial designed to enroll 180 myelofibrosis patients who are symptomatic and anemic, and who have been treated previously with a JAK inhibitor.

The U.S. Food and Drug Administration has granted Fast Track designation to momelotinib.

Momelotinib is protected by numerous issued patents and pending applications globally, with patent exclusivity potentially extending to 2040.